prothena corporation plc (nasdaq: prta) is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. the company focuses on therapeutic monoclonal antibodies directed specifically to disease-causing proteins, and its antibody-based product candidates target a number of potential indications, including al amyloidosis (neod001), parkinson’s disease and other related synucleinopathies (prx002), and novel cell adhesion targets involved in psoriasis and other inflammatory diseases (prx003). our lead program, neod001, is in a global phase 3 registration clinical trial – the vital amyloidosis study. there is also an on-going phase 1/2 trial. prx002 is in a phase 1 multiple ascending dose clinical trial, and prx003 is in a phase 1 single ascending dose clinical trial. prothena’s elite team has a recognized track record both f
Company profile
Ticker
PRTA
Exchange
Website
CEO
Gene Kinney
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Neotope Corp Ltd, Prothena Corp plc
SEC CIK
Corporate docs
Subsidiaries
Prothena Biosciences Limited • Prothena Biosciences Inc • Prothena Finance Inc • Othair Prothena Limited • Prothena Pharma Limited • Prothena Platform Technologies Limited ...
PRTA stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
29 Mar 24
DEFA14A
Additional proxy soliciting materials
29 Mar 24
DEF 14A
Definitive proxy
29 Mar 24
S-3ASR
Automatic shelf registration
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
8-K
Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights
15 Feb 24
8-K
Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Prothena Reports Third Quarter 2023 Financial Results and Business Highlights
2 Nov 23
Transcripts
PRTA
Earnings call transcript
2023 Q4
15 Feb 24
PRTA
Earnings call transcript
2022 Q4
23 Feb 23
PRTA
Earnings call transcript
2021 Q4
18 Feb 22
PRTA
Earnings call transcript
2020 Q4
11 Feb 21
PRTA
Earnings call transcript
2019 Q4
12 Feb 20
PRTA
Earnings call transcript
2018 Q4
15 Feb 19
PRTA
Earnings call transcript
2017 Q4
14 Feb 18
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 673.11 mm | 673.11 mm | 673.11 mm | 673.11 mm | 673.11 mm | 673.11 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 8.39 mm | (no burn) | 7.32 mm |
Cash used (since last report) | n/a | n/a | n/a | 56.97 mm | n/a | 49.72 mm |
Cash remaining | n/a | n/a | n/a | 616.14 mm | n/a | 623.39 mm |
Runway (months of cash) | n/a | n/a | n/a | 73.4 | n/a | 85.2 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 188 |
Opened positions | 28 |
Closed positions | 36 |
Increased positions | 72 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 2.53 tn |
Total shares | 63.00 mm |
Total puts | 357.90 k |
Total calls | 187.10 k |
Total put/call ratio | 1.9 |
Largest owners | Shares | Value |
---|---|---|
EcoR1 Capital | 11.58 mm | $558.94 bn |
EcoR1 Capital Fund | 10.31 mm | $235.58 mm |
FMR | 8.03 mm | $387.46 bn |
T. Rowe Price | 3.82 mm | $185.25 bn |
BLK Blackrock | 3.54 mm | $170.87 bn |
Wellington Management | 2.14 mm | $103.33 bn |
STT State Street | 2.11 mm | $101.82 bn |
JHG Janus Henderson | 1.83 mm | $88.13 bn |
Palo Alto Investors | 1.66 mm | $79.97 bn |
First Light Asset Management | 1.49 mm | $72.09 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Ford David A | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 28.53 | 85,000 | 2.43 mm | 85,000 |
27 Feb 24 | Wagner M. Zago | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 30.3 | 85,000 | 2.58 mm | 85,000 |
27 Feb 24 | Walker Karin L | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 30.3 | 54,000 | 1.64 mm | 54,000 |
27 Feb 24 | Brandon S. Smith | Stock Option Ordinary Shares | Grant | Acquire A | No | No | 30.3 | 85,000 | 2.58 mm | 85,000 |
News
Prothena Announces Review On Birtamimab Mechanism Of Action And Pharmacological Characteristics Published In Leukemia & Lymphoma
15 Apr 24
Cantor Fitzgerald Reiterates Overweight on Prothena Corp
10 Apr 24
Demystifying Prothena Corp: Insights From 8 Analyst Reviews
13 Mar 24
HC Wainwright & Co. Maintains Buy on Prothena Corp, Maintains $90 Price Target
13 Mar 24
10 Health Care Stocks Whale Activity In Today's Session
29 Feb 24